Neoadjuvant Treatment of Breast Cancer - a Prospective Observational Study, PANnon ONCology (PANONC) Group Non-commercial Clinical Trial
Latest Information Update: 29 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Tamoxifen (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms PANONC
Most Recent Events
- 29 Nov 2021 New trial record